Foetal bovine serum (FBS) is a universally used supplement in mammalian cell culture and biomanufacturing due to its rich composition of growth factors, hormones, and nutrients that support robust cell growth and maintenance. FBS is derived from the blood of bovine fetuses, usually as a byproduct of the meat industry, and its use is both widespread and controversial due to ethical, regulatory, and scientific concerns.
Variability in Composition
FBS is obtained from fetal calves originating from various regions, such as Europe, the United States, Australia, and others. Each origin may exhibit variations in FBS composition due to factors such as diet, environment, and husbandry practices. Variability may affect concentrations of proteins, growth factors, endotoxin levels, and small metabolites, which can in turn influence biological outcomes in cell culture—especially in immune and signaling assays. This inconsistency has been shown to impact experimental reproducibility and the expression of sensitive biomarkers such as interleukin-8 (IL-8) in cultured cells.
A comparison of FBS from different origins (e.g., Australia, New Zealand, South America, United States) using various cell lines has shown little observable difference in cell growth performance across most standard lines, provided that the serum meets regulatory and safety guidelines. Safety testing and sterilization processes mandated for importation into the US and EU help standardize the quality and safety of FBS worldwide.
Conclusion
FBS remains an essential reagent for cell culture due to its unique blend of nutrients but presents challenges in terms of ethical sourcing, regulatory acceptance, batch-to-batch consistency, and cost.
Geographic origin has minimal impact on cell culture performance, assuming equivalent collection and processing controls and regulatory compliance, though it influences price, traceability, and regulatory hurdles.
